Business
Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland
Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company's first manufacturing presence in the United States.
About this update from Samsung Biologics Co., Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"Marks Samsung Biologics' geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support","length":146,"tagName":"p"}]},{"val":[{"type":"text","content":"Plans further investments to add capabilities and strengthen long-term operations at the Rockville site","length":103,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":332,"olType":false},{"type":"text","content":"INCHEON, South Korea and ROCKVILLE, MD., March 31, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company's first manufacturing presence in the United States.","length":370,"tagName":"p"},{"type":"image","alt":"Samsung Biologics Logo (PRNewsfoto/Samsung Biologics)","displaySize":"","headline":null,"caption":"Samsung Biologics Logo (PRNewsfoto/Samsung Biologics)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/35fb5e8461f86f1d8888f5be2870db4d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QvbwjAh63ERdlRKsBA22Rg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNQ--/https://media.zenfs.com/en/prnewswire.com/35fb5e8461f86f1d8888f5be2870db4d","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/2395686/Samsung_Biologics_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales. With this addition, Samsung Biologics' total global manufacturing capacity increases to 845,000 liters.","length":319,"tagName":"p"},{"type":"text","content":"Samsung Biologics will continue supplying the products previously manufactured at the site to GSK under the terms of the agreement, and the site will transition to serve additional contract manufacturing needs. Samsung Biologics also plans further investments to ex...